Assessment of non-derivatized beta-N-methylamino-L-alanine
(BMAA) neurotoxin in free form in urine of patients with
nonspecific neurological symptoms

J 2017

Assessment of non-derivatized beta-N-methylamino-L-alanine (BMAA) neurotoxin in free form in urine of patients with nonspecific neurological symptoms

BLÁHOVÁ, Lucie, Jiří KOHOUTEK, E. KADLECOVA, L. KOZAKOVA, Luděk BLÁHA et. al.

Basic information

Original name

Assessment of non-derivatized beta-N-methylamino-L-alanine (BMAA) neurotoxin in free form in urine of patients with nonspecific neurological symptoms

Authors

BLÁHOVÁ, Lucie (203 Czech Republic, belonging to the institution), Jiří KOHOUTEK (203 Czech Republic, belonging to the institution), E. KADLECOVA (203 Czech Republic), L. KOZAKOVA (203 Czech Republic) and Luděk BLÁHA (203 Czech Republic, guarantor, belonging to the institution)

Edition

Toxicon, OXFORD, PERGAMON-ELSEVIER SCIENCE LTD, 2017, 0041-0101

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.352

RIV identification code

RIV/00216224:14310/17:00100223

Organization unit

Faculty of Science

DOI

http://dx.doi.org/10.1016/j.toxicon.2017.04.011

UT WoS

000403864000006

Keywords in English

Liquid chromatography-tandem mass spectrometry (LC-MS/MS); Hydrophilic interaction liquid chromatography (HILIC); Beta-N-methylamino-L-alanine (BMAA); Human urine

Abstract

V originále

The beta-N-methylamino-L-alanine (BMAA) is a non-proteinogenic amino acid discussed to be produced by cyanobacteria forming harmful blooms. Since BMAA is suspected etiological agent in neurodegenerative diseases, there is a need to study and validate whether and in what concentrations can BMAA be present in human tissues. The aim of the present study was to validate analytical and extraction procedures for quantification of non-derivatized BMAA in the urine using liquid chromatography and commercial ELISA Kit. The study was focused on BMAA in different forms - dissolved, protein associated and total. The validated protocol included SPE followed by HILIC MS/MS for analyses of non-derivatized free form of BMAA with a limit of quantification 20 ng/mL. The methods for other BMAA forms (i.e.protein-associated and total) were also assessed but high matrix interferences did not allow their implementation. The method was used for analyses of free BMAA in 23 urine samples from healthy volunteers and psychiatric patients suffering from nonspecific neurological symptoms. Traces of BMAA were suspectedly detected in a single urine sample but they were not unequivocally proved according to all conservative analytical criteria. BMAA was also not confirmed in a repeatedly collected sample from the same person. The evaluated commercial BMAA ELISA Kit (Abraxis) was not suitable for determination of BMAA in extracted urine samples because of systematically highly false positive results. In agreement with recent findings, analyses of BMAA appear to methodologically challenging, and further research on BMAA in human tissues (or its precursors with potency to form BMAA under natural conditions or eventually - during sample processing) is needed to clarify its potential ethiological role in neurodegenerative diseases.

Links

LM2015051, research and development project

Name: Centrum pro výzkum toxických látek v prostředí (Acronym: RECETOX RI)

Investor: Ministry of Education, Youth and Sports of the CR

LO1214, research and development project

Name: Centrum pro výzkum toxických látek v prostředí (Acronym: RECETOX)

Investor: Ministry of Education, Youth and Sports of the CR

Citovat

BLÁHOVÁ, Lucie, Jiří KOHOUTEK, E. KADLECOVA, L. KOZAKOVA and Luděk BLÁHA. Assessment of non-derivatized beta-N-methylamino-L-alanine (BMAA) neurotoxin in free form in urine of patients with nonspecific neurological symptoms. Toxicon. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD, 2017, vol. 133, July, p. 48-57. ISSN 0041-0101. Available from: https://dx.doi.org/10.1016/j.toxicon.2017.04.011.

@article{1410112,
   author = {Bláhová, Lucie and Kohoutek, Jiří and Kadlecova, E. and Kozakova, L. and Bláha, Luděk},
   article_location = {OXFORD},
   article_number = {July},
   doi = {http://dx.doi.org/10.1016/j.toxicon.2017.04.011},
   keywords = {Liquid chromatography-tandem mass spectrometry (LC-MS/MS); Hydrophilic interaction liquid chromatography (HILIC); Beta-N-methylamino-L-alanine (BMAA); Human urine},
   language = {eng},
   issn = {0041-0101},
   journal = {Toxicon},
   title = {Assessment of non-derivatized beta-N-methylamino-L-alanine (BMAA) neurotoxin in free form in urine of patients with nonspecific neurological symptoms},
   url = {https://www.sciencedirect.com/science/article/pii/S0041010117301277?via%3Dihub},
   volume = {133},
   year = {2017}
}

TY  - JOUR
ID  - 1410112
AU  - Bláhová, Lucie - Kohoutek, Jiří - Kadlecova, E. - Kozakova, L. - Bláha, Luděk
PY  - 2017
TI  - Assessment of non-derivatized beta-N-methylamino-L-alanine (BMAA) neurotoxin in free form in urine of patients with nonspecific neurological symptoms
JF  - Toxicon
VL  - 133
IS  - July
SP  - 48-57
EP  - 48-57
PB  - PERGAMON-ELSEVIER SCIENCE LTD
SN  - 00410101
KW  - Liquid chromatography-tandem mass spectrometry (LC-MS/MS)
KW  - Hydrophilic interaction liquid chromatography (HILIC)
KW  - Beta-N-methylamino-L-alanine (BMAA)
KW  - Human urine
UR  - https://www.sciencedirect.com/science/article/pii/S0041010117301277?via%3Dihub
L2  - https://www.sciencedirect.com/science/article/pii/S0041010117301277?via%3Dihub
N2  - The beta-N-methylamino-L-alanine (BMAA) is a non-proteinogenic amino acid discussed to be produced by cyanobacteria forming harmful blooms. Since BMAA is suspected etiological agent in neurodegenerative diseases, there is a need to study and validate whether and in what concentrations can BMAA be present in human tissues. The aim of the present study was to validate analytical and extraction procedures for quantification of non-derivatized BMAA in the urine using liquid chromatography and commercial ELISA Kit. The study was focused on BMAA in different forms - dissolved, protein associated and total. The validated protocol included SPE followed by HILIC MS/MS for analyses of non-derivatized free form of BMAA with a limit of quantification 20 ng/mL. The methods for other BMAA forms (i.e.protein-associated and total) were also assessed but high matrix interferences did not allow their implementation. The method was used for analyses of free BMAA in 23 urine samples from healthy volunteers and psychiatric patients suffering from nonspecific neurological symptoms. Traces of BMAA were suspectedly detected in a single urine sample but they were not unequivocally proved according to all conservative analytical criteria. BMAA was also not confirmed in a repeatedly collected sample from the same person. The evaluated commercial BMAA ELISA Kit (Abraxis) was not suitable for determination of BMAA in extracted urine samples because of systematically highly false positive results. In agreement with recent findings, analyses of BMAA appear to methodologically challenging, and further research on BMAA in human tissues (or its precursors with potency to form BMAA under natural conditions or eventually - during sample processing) is needed to clarify its potential ethiological role in neurodegenerative diseases.
ER  -

BLÁHOVÁ, Lucie, Jiří KOHOUTEK, E. KADLECOVA, L. KOZAKOVA and Luděk BLÁHA. Assessment of non-derivatized beta-N-methylamino-L-alanine (BMAA) neurotoxin in free form in urine of patients with nonspecific neurological symptoms. \textit{Toxicon}. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD, 2017, vol.~133, July, p.~48-57. ISSN~0041-0101. Available from: https://dx.doi.org/10.1016/j.toxicon.2017.04.011.

Detailed Information on Publication Record